Scholar Rock Does Its Homework For Successful SMA Launch

 
• By Kevin Grogan

On the back of a stellar showing in Phase III, apitegromab is going to be filed in the US and Europe in the coming weeks for spinal muscular atrophy and CEO Jay Backstrom believes it will be a $2bn blockbuster.

Spinal muscular atrophy
• Source: Shutterstock

More from Start-Ups & SMEs

More from Therapy Areas